100 INTERNATIONAL, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF CC-486 (ORAL AZACITIDINE) IN PATIENTS WITH IPSS INTERMEDIATE-1 MYELODYSPLASTIC SYNDROMES WITH RBC-TRANSFUSION-DEPENDENT ANEMIA AND THROMBOCYTOPENIA: THE QUAZAR LOWER-RISK MDS TRIAL. Issue 1 (April 2015) - Garcia-Manero, G.; Platzbecker, U.; Santini, V.; Voso, M.T.; Garcia, R.; Valcarcel, D.; Silverman, L.R.; Almeida, A.; Giagounidis, A.; Larsen, S.R.; Kreitz, S.; Hoenekopp, A.; et al.